Four Riffs on Rivaroxaban vs. Warfarin


Ron Winslow on the WSJ Health Blog points out the interesting and slightly different interpretations of the very same clinical study presented yesterday at the  late-breaking sessions of the American Heart Association’s Scientific Meeting.

Here are the four PR riffs on Rivaroxaban vs. Warfarin, aka Coumadin, for Afib and Stroke:  Duke, JNJ, Bayer and the AHA weigh in.

You can see the slides and hear the presentation by scrolling down to the ROCKET AF section here.

Watch the video, read Ron’s article, and tell us:  what do you think?

To keep up with the best in Good Promotional Practices, subscribe to our GPP RSS feed, our Facebook page, our Twitter stream or our LinkedIn group.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s